Through recent research advances we are increasingly able to understand and address immune-mediated diseases. Biotechnology is yielding success in areas with a strong immunologic component, such as allergic asthma, rheumatoid arthritis, inflammatory bowel disease, psoriasis and multiple sclerosis. Nevertheless, the burden of immune-mediated diseases is still enormous, with direct and indirect costs associated with such conditions believed to exceed $100 billion in the USA alone. Expert Review of Clinical Immunology (ISSN 1744-666X) is a MEDLINE-indexed, international subscription-based journal publishing rigorously peer-reviewed review articles and original papers regarding the performance of new therapeutic and diagnostic modalities in clinical immunology. Members of the International Editorial Advisory Panel of Expert Review of Clinical Immunology are the forefront of their area of expertise. This panel works with our dedicated editorial team to identify the most important and topical review themes and the corresponding expert(s) most appropriate to provide commentary and analysis. All articles are subject to rigorous peer-review, and the finished reviews provide an essential contribution to decision-making in clinical immunology. Articles focus on the following key areas: • Therapeutic overviews of specific immunologic disorders highlighting optimal therapy and prospects for new medicines • Performance and benefits of newly approved therapeutic agents • New diagnostic approaches • Screening and patient stratification • Pharmacoeconomic studies • New therapeutic indications for existing therapies • Adverse effects, occurrence and reduction • Prospects for medicines in late-stage trials approaching regulatory approval • Novel treatment strategies • Epidemiological studies • Commentary and comparison of treatment guidelines

Expert Review of Clinical Immunology (ERCI) is :

International, Peer-Reviewed, Open Access, Refereed, allergic asthma, rheumatoid arthritis, inflammatory bowel disease, psoriasis, multiple sclerosis, Adverse effects, occurrence and reduction, Epidemiological studies , Online or Print, Bi-Monthly Journal

UGC Approved, ISSN Approved: P-ISSN - 1744-666X, E-ISSN - 1744-8409, Established in - 2025, Impact Factor - 3.9

Provide Crossref DOI

Indexed in Scopus, WoS

Not indexed in DOAJ, PubMed, UGC CARE